BIIB · BIOGEN INC.

Model classification: Undervalued, Above Safe Price

Price is below our Estimated Fair Value but above our Safe Price.

Market Price
$208.87
Aug 13, 2026
Estimated Fair Value
$275.06
Safe Price (90%)
$99.89
Through next 1 filing

The numbers

$99.89Safe Price (90%)$275.06Fair Value$208.87Market
Gap to Fair Value
$66.19 below
+31.7%
Gap to Safe Price
$108.98 above
−52.2%
Based on filings through Aug 13, 2026 · Valuation of Aug 13, 2026

What this means

The market price is below our Estimated Fair Value but remains above the Safe Price. A discount exists, but it has not reached the calibrated safety threshold.

We recheck this valuation when a new SEC filing lands, when market price crosses our Safe Price, or when the safe horizon expires — whichever comes first.

Model output · Education, not advice. Full disclaimer. Figures are model outputs from public SEC filings, not recommendations.